Kenvue Inc. to Issue Quarterly Dividend of $0.21 (NYSE:KVUE)

Kenvue Inc. (NYSE:KVUE) announced a quarterly dividend on Thursday, January 16th,Wall Street Journal reports. Investors of record on Wednesday, February 12th will be paid a dividend of 0.205 per share on Wednesday, February 26th. This represents a $0.82 annualized dividend and a yield of 3.89%. The ex-dividend date is Wednesday, February 12th.

Kenvue has a dividend payout ratio of 63.1% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Kenvue to earn $1.20 per share next year, which means the company should continue to be able to cover its $0.82 annual dividend with an expected future payout ratio of 68.3%.

Kenvue Stock Performance

Shares of KVUE stock opened at $21.11 on Friday. Kenvue has a 52 week low of $17.67 and a 52 week high of $24.46. The firm has a 50 day moving average of $22.42 and a two-hundred day moving average of $21.66. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $40.46 billion, a PE ratio of 38.37, a P/E/G ratio of 1.99 and a beta of 1.46.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. Kenvue’s revenue for the quarter was down .4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.31 EPS. On average, research analysts predict that Kenvue will post 1.14 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on KVUE shares. Citigroup reduced their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday. Barclays cut their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday. Bank of America upped their price objective on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. Royal Bank of Canada raised Kenvue from a “hold” rating to a “moderate buy” rating in a research report on Monday, December 9th. Finally, Jefferies Financial Group assumed coverage on shares of Kenvue in a research report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price target for the company. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.